Bejelentkezés Regisztrálj ingyen

Edesa Biotech Adósság / tőke

Mi az Edesa Biotech Adósság / tőke?

A Adósság / tőke az Edesa Biotech, Inc. - 0.26

Mi a Adósság / tőke meghatározása?



Az adósság és a saját tőke aránya a társasági eszközök finanszírozásához használt saját tőke és adósság viszonylagos arányát jelző pénzügyi arány.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Adósság / tőke a Health Care szektor a NASDAQ-on cégekben a Edesa Biotech -hoz képest

Mit csinál Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

adósság / tőke -hoz hasonló cégek Edesa Biotech